Robert W. Rieder
Directeur/Membre du Conseil chez Verity Pharmaceuticals, Inc.
Profil
Robert W.
Rieder is currently a Director at Verity Pharmaceuticals, Inc. He was previously the President & CEO of ESSA Pharma, Inc. from 2010 to 2016, and the President, CEO, Director & IR Contact from 2010 to 2016.
He was also the Non-Executive Chairman at Correvio Pharma Corp.
in 2015, and the Chairman at Akela Pharma, Inc. from 2009 to 2012.
Additionally, he served as a Director at Nventa Biopharmaceuticals Corp., BC Advantage Funds Ltd., Trillium Therapeutics ULC, Bradmer Pharmaceuticals, Inc., Inovio Pharmaceuticals, Inc., XORTX Pharma Corp., and Magnum Uranium Corp.
He was also the Chief Operating Officer at Magnum Uranium Corp.
and DBA Telecommunication (Asia) Holdings Ltd.
Furthermore, he was the Vice President at MDS Ventures Pacific, Inc. Mr. Rieder received his undergraduate degree from the University of British Columbia and his MBA from the Richard Ivey School of Business.
Postes actifs de Robert W. Rieder
| Sociétés | Poste | Début |
|---|---|---|
Verity Pharmaceuticals, Inc.
 Verity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Verity Pharmaceuticals, Inc. operates as a pharmaceutical company. It provides therapeutically relevant agents to the Canadian healthcare community. The company was founded in 2016 and is headquartered in Mississauga, ON. | Directeur/Membre du Conseil | - |
Anciens postes connus de Robert W. Rieder
| Sociétés | Poste | Fin |
|---|---|---|
| ESSA PHARMA INC. | Directeur Général | 07/01/2016 |
| CORREVIO PHARMA CORP. | Directeur Général | 01/08/2009 |
Akela Pharma, Inc.
 Akela Pharma, Inc. Pharmaceuticals: MajorHealth Technology Akela Pharma, Inc. operates as a drug development company, which develops and manufactures pharmaceutical formulations and drugs. The company operates as a specialty contract pharmaceutical formulation developer and clinical and commercial drug manufacturer for proprietary drug products through its wholly-owned subsidiary, PharmaForm LLC, a pharmaceutical intellectual property development company. It provides specialty contract services in the area of pharmaceutical dosage form development, preclinical, scale-up, clinical and commercial supply manufacturing, focusing on controlled release and bioavailability enhancement technologies, such as hot melt extrusion, spray drying and liquid filled capsules. Akela Pharma was founded on November 15, 1988 and is headquartered in Austin, TX. | Président | 18/07/2012 |
| TRILLIUM THERAPEUTICS | Directeur/Membre du Conseil | 24/06/2010 |
| INOVIO PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/06/2009 |
Formation de Robert W. Rieder
| University of British Columbia | Undergraduate Degree |
| Richard Ivey School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| INOVIO PHARMACEUTICALS, INC. | Health Technology |
| ESSA PHARMA INC. | Health Technology |
| Entreprise privées | 12 |
|---|---|
Nventa Biopharmaceuticals Corp.
 Nventa Biopharmaceuticals Corp. Medical SpecialtiesHealth Technology Nventa Biopharmaceuticals Corp. discovered, developed and commercialized stress protein-based therapeutic vaccines. The company was headquartered in Victoria, Canada. | Health Technology |
Correvio Pharma Corp.
 Correvio Pharma Corp. Pharmaceuticals: MajorHealth Technology Correvio Pharma Corp. operates as a pharmaceutical company, which engages in the provision of development and commercialization of medical products. It operates through the Europe and Rest of the World geographical segments. The firm focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. It offers the Brinavess and Aggrastat products to customers such as physicians, patients and healthcare systems. The company was founded in 1986 and is headquartered in Vancouver, Canada. | Health Technology |
Magnum Uranium Corp.
 Magnum Uranium Corp. Other Metals/MineralsNon-Energy Minerals Magnum Uranium Corp. (MM:TSX.V) is a Canadian-based exploration company focused on the acquisition and development of a high-quality portfolio of uranium properties. Magnum's corporate strategy is to acquire advanced-stage uranium properties that are either past producers, have been the subject of prior work programs and/or contain historic resources. Additionally, Magnum will acquire selective early-stage properties should they possess significant geologic merit. Magnum has a proven track record of acquiring projects that meet these criteria as evidenced by its present portfolio. Company's geographic focus is the Western United States, where it have acquired uranium properties in Idaho, Utah, Wyoming, New Mexico, and Canada's Athabasca Basin. The company was founded in 1984 and is headquartered in Vancouver, Canada. | Non-Energy Minerals |
BC Advantage Funds Ltd.
 BC Advantage Funds Ltd. Investment ManagersFinance Founded 2003, BC Advantage Funds (VCC) Ltd is a venture capital firm, headquartered in Canada. | Finance |
Trillium Therapeutics ULC
 Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
Bradmer Pharmaceuticals, Inc.
 Bradmer Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bradmer Pharmaceuticals, Inc. engaged in the development and commercialization of cancer therapies. The company was founded on June 16, 2005 and wass headquartered in Toronto, Canada. | Commercial Services |
DBA Telecommunication (Asia) Holdings Ltd.
 DBA Telecommunication (Asia) Holdings Ltd. Computer PeripheralsElectronic Technology DBA Telecommunication (Asia) Holdings Ltd. is an investment holding company, which provides intelligent payment services. The company operates through the following segments: Information Technology, Intelligent Self-service and Agency. The Information Technology segment designs, manufactures and sells telecommunication equipment and related products. The Intelligent Self-service segment engages in payment service in public utility including pre-paid phone cards, water, electricity and gas through sales of pre-paid cards and recharging services. It also provides electronic payment and settlement services. The Agency segment engages in trading of telecommunication products. The company was founded on June 15, 2004 and is headquartered in Hong Kong. | Electronic Technology |
Synapse Technologies, Inc.
 Synapse Technologies, Inc. Pharmaceuticals: MajorHealth Technology Synapse Technologies Inc. develops an Alzheimer's diagnostic test and potential blood/brain drug delivery mechanism based on the p97 protein. | Health Technology |
| MDS Ventures Pacific, Inc. | |
Akela Pharma, Inc.
Akela Pharma, Inc. Pharmaceuticals: MajorHealth Technology Akela Pharma, Inc. operates as a drug development company, which develops and manufactures pharmaceutical formulations and drugs. The company operates as a specialty contract pharmaceutical formulation developer and clinical and commercial drug manufacturer for proprietary drug products through its wholly-owned subsidiary, PharmaForm LLC, a pharmaceutical intellectual property development company. It provides specialty contract services in the area of pharmaceutical dosage form development, preclinical, scale-up, clinical and commercial supply manufacturing, focusing on controlled release and bioavailability enhancement technologies, such as hot melt extrusion, spray drying and liquid filled capsules. Akela Pharma was founded on November 15, 1988 and is headquartered in Austin, TX. | Health Technology |
XORTX Pharma Corp.
 XORTX Pharma Corp. Pharmaceuticals: MajorHealth Technology XORTX Pharma Corp. engages in the discovery, development, and commercialization of therapies for rare diseases. It develops cardio-vascular medications for the treatment of rare diseases such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, cystic fibrosis as well as large market diseases such as hypertension, metabolic syndrome, diabetes, and diabetic nephropathy. The company was founded in 2012 and is headquartered in Calgary, Canada. | Health Technology |
Verity Pharmaceuticals, Inc.
Verity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Verity Pharmaceuticals, Inc. operates as a pharmaceutical company. It provides therapeutically relevant agents to the Canadian healthcare community. The company was founded in 2016 and is headquartered in Mississauga, ON. | Health Technology |
